Immuno-oncological era of breast cancer: A progressive path to better treatment
Open Access
- 18 May 2022
- journal article
- Published by Scientific Scholar in International Journal of Molecular and Immuno Oncology
Abstract
Breast cancer was initially thought to be less immunogenic; however, extensive studies in recent years have transcended into one having high mutagenic potential. The molecular classification of breast cancer has taken giant strides, as to having subtypes in triple negative breast cancer (TNBC) as proposed by Lehmann and group. This recent development has been studied extensively in the immunotherapy trials, the most recent one being the IMPASSION 130 trial which introduced the drug – Atezolizumab. In addition, tissue infiltrating lymphocytes have also been researched in the treatment of residual tumors in post-neoadjuvant scenarios. Vaccines, CART cell therapy, and antibodies are being developed in breast cancer just like the immunotherapeutic strategies in other cancers. This review is an attempt to present the ongoing developments in the field of immunotherapy in breast cancer with highlights in TNBC’s, metastatic breast cancer, and hereditary BRCA positive cancers in particular.Keywords
This publication has 21 references indexed in Scilit:
- Immunotherapy for metastatic breast cancerChinese Clinical Oncology, 2018
- Immunooncology in Breast Cancer: Active and Passive Vaccination StrategiesBreast Care, 2018
- Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast CancerSeminars in Cancer Biology, 2017
- Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 StudyJournal of Clinical Oncology, 2016
- Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199Journal of Clinical Oncology, 2014
- The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014Annals of Oncology, 2014
- Primary analysis of the prospective, randomized, phase II trial of GP2+GM-CSF vaccine versus GM-CSF alone administered in the adjuvant setting to high-risk breast cancer patients.Journal of Clinical Oncology, 2014
- The immunogenicity of breast cancer—molecular subtypes matterAnnals of Oncology, 2014
- Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trialThe Lancet Oncology, 2014
- Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98Journal of Clinical Oncology, 2013